Abstract:OBJECTIVE To evaluate the efficacy and economy of cefoperazone-sulbactam, imipenem-cilastatin, and piperacillin-tazobactam in treatment of gram-negative bacteria infections.METHODS By means of non-random observational study, the data of antibiotics therapy were collected from 322 patients with gram-negative bacteria infections who were hospitalized from Jan 1, 2012 to May 11, 2016 and were treated with cefoperazone-sulbactam, imipenem-cilastatin, and piperacillin-tazobactam.The pharmacoeconomics were evaluated with the use of cost-effectiveness analysis method.RESULTS The data were obtained from a large sample, non-random, and active surveillance study, the between-group covariate imbalance phenomenon existed in the original data, and the between-group covariate imbalance phenomenon was remarkably improved after they were matched by using propensity scoring method.After the matching, the economic analysis of costs of target antibiotics was carried out after the matching.As compared with cefoperazone-sulbactam and imipenem-cilastatin, cefoperazone-sulbactam that obtained every 1% clinical efficacy, microbial efficacy, comprehensive effect, and 30-day survival rate only needed 39.15 yuan, 51.02 yuan, 52.61 yuan, and 40.09 yuan, respectively;while the imipenem-cilastatin needed 75.54 yuan, 81.28 yuan, 83.39 yuan, and 72.15 yuan respectively.As compared with cefoperazone-sulbactam and piperacillin-tazobactam, cefoperazone-sulbactam that obtained every 1% clinical efficacy, microbial efficacy, comprehensive effect, and 30-day survival rate only needed 36.94 yuan, 46.80 yuan, 48.40 yuan, and 33.42 yuan, respectively;while piperacillin-tazobactam needed 99.99 yuan, 117.64 yuan, 121.21 yuan, and 95.23 yuan, respectively.The four cost-effectiveness analyses showed that cefoperazone-sulbactam had obvious economic advantages.Under the circumstances of the same efficacy, the cost of cefoperazone-sulbactam was 1/3~1/2 of the cost of piperacillin-tazobactam and imipenem-cilastatin.The sensitivity analysis based on the 95% confidence limit of efficacy showed that the conclusion remained true.CONCLUSION Cefoperazone-sulbactam has more cost-effectiveness advantages on treatment of the gram-negative bacteria (including multidrug-resistant organisms) infections.

The susceptibility of non-fermentative Gram-negative bacilli to cefperazone and sulbactam compared with other antibacterial agents.

Antimicrobial Agents Including Cefmetazole Against Extended-spectrum Beta-lactamases-producing Enterobacteriaceae: an in Vitro Susceptibility Investigation

Antibacterial Activity of Cefoperazone-Sulbactam Against Nonfermentative Gram Negative Rods

A multicenter study on the in vitro antibacterial activity of cefoselis against common clinical bacteria

Antimicrobial Susceptibilitytesting of Non-Fermentative Bacteria in 15 Teaching Hospitals in China: a Report from SEANIR Antimicrobial Resistance Surveillance 2008

Investigation of antibacteriocidal activity of domestic meropenem on β-lacta-mases-producing gram negativ bacilli in vitro

Comparison of antimicrobial activity in vitro of 7 β-lactams against 280 isolates from patients with nosocomial infections

Comparison of antibacterial activities of cefepime and 4 others antibiotics against gram-negative Bacilli isolated

Comparison of antibacterial activities of different concentrations of the cefoperazone-sulbactam combination disc upon commonly found gram negative bacilli

Susceptibility of Cefiderocol and Other Antibiotics Against Carbapenem-Resistant, Gram-negative Bacteria

Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam

In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021

Resistance Surveillance of 400 Gram-negative Bacterial Isolates from Intensive Care Unit with E-test

Changing pattern of bacterial resistance in Gram negative bacilli

Pharmacodynamic Target Attainment of Seven Antimicrobials Against Gram-negative Bacteria Collected from China in 2003 and 2004.

Antibacterial Activity of Cefepime on the Clinically Common Pathogenic Bacteria:Survey of 576 Strains

Analysis on the resistance of clinically cefoxitin -non -susceptible Klebsiella pneumoniae isolates and prevalence of β-lactamase

Evaluation of the in Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Meropenem-Resistant Pseudomonas Aeruginosa Isolates.

Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of <i>Enterobacterales</i> and Pseudomonas aeruginosa

In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens from Various Complicated Infections in China.

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)